Background

Qualitest, a leading developer and manufacturer of affordable, high-quality generic pharmaceuticals, launched a compliance audit strategy to prepared for upcoming FDA inspections.

To protect public safety, the U.S. Food and Drug Administration (FDA) routines audits and assesses companies that manufacture and package drugs. Qualitest wanted to better understand the unique conditions that violate FDA regulations. The leadership team was not in fear of receiving a FDA warning letter. However, being proactive to stay in compliance was the root focus of the strategy.

Solution

Qualitest engaged Regulatory Compliance Associates^® Inc. (RCA) to prepare the company in advance of an FDA Audit. RCA reviewed over 170 investigations relating to Qualitest operations to suggest improvements and identify areas of risk.

RCA conducted a mock audit to both ensure the compliance of the client and to maintain their readiness for the actual FDA inspection. RCA’s experienced team of ASQ-CQA and Exemplar Global certified auditors was available to perform a range of internal audit services, including:

• Supplier
• API
• Contact Manufactures (CMO)
• Internal
• Quality Systems
• Baseline
• Verification
• Clinical (CRO) and Clinical Manufacturing
• Data Integrity
• 503A & 503B
• Combination Products

By working efficiently and by tapping into scheduled downtime, RCA was able to complete the project in three months.

Result

Qualitest implemented the recommended changes, including company-wide training, and received no observations during the next FDA inspection.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage.